Study Design
This is a prospective, longitudinal, observational registry study to provide a unique and effective mechanism to acquire real-world data on product prescribing, product use by patients, and product performance for patients (any age) receiving immunoglobulin therapy (intravenous and or subcutaneous) in a home care and/or Coram ambulatory infusion setting, regardless of disease treated.
The IDEaL Registry is not being developed to answer specific hypotheses; therefore, there are no sample size requirements for this registry. The goal of the IDEaL Registry is to descriptively summarize the real-world treatment space of Ig therapy and therefore it was determined that it would be important to ensure that there are sites from across the U.S. (e.g., to describe any geographical trends) and sites from the different therapeutic indications (i.e., immunological and neurologic specialties).
